Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 ...

Ltd., widely known as Baurs, a leading conglomerate with diversified business interests in Sri Lanka and a pioneer and ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, ...